Literature DB >> 19681047

Kinetics of transport and phosphorylation of glucose in cancer cells.

Sara Rodríguez-Enríquez1, Alvaro Marín-Hernández, Juan Carlos Gallardo-Pérez, Rafael Moreno-Sánchez.   

Abstract

Metabolic control analysis of tumor glycolysis has indicated that hexokinase (HK) and glucose transporter (GLUT) exert the main flux control (71%). To understand why they are the main controlling steps, the GLUT and HK kinetics and the contents of GLUT1, GLUT2, GLUT3, GLUT4, HKI, and HKII were analyzed in rat hepatocarcinoma AS-30D and HeLa human cervix cancer. An improved protocol to determine the kinetic parameters of GLUT was developed with D-[2-(3)H-glucose] as physiological substrate. Kinetic analysis revealed two components at low- and high-glucose concentrations in both tumor cells. At low glucose and 37 degrees C, the V(max) was 55 +/- 20 and 17.2 +/- 6 nmol (min x mg protein)(-1), whereas the K(m) was 0.52 +/- 0.7 and 9.3 +/- 3 mM for hepatoma and HeLa cells, respectively. GLUT activity was partially inhibited by cytochalasin B (IC(50) = 0.44 +/- 0.1; K(i) = 0.3 +/- 0.1 microM) and phloretin (IC(50) = 8.7 microM) in AS-30D hepatocarcinoma. At physiological glucose, GLUT1 and GLUT3 were the predominant active isoforms in HeLa cells and AS-30D cells, respectively. HK activity in HeLa cells was much lower (60 mU/mg protein) than that in AS-30D cells (700 mU/mg protein), but both HKs were strongly inhibited by G6P. HKII was the predominant isoform in AS-30D carcinoma and HeLa cells. The much lower GLUT V(max) and catalytic efficiency (V(max)/K(m)) values in comparison to those of G6P-sensitive HK suggested the transporter exerts higher control on the glycolytic flux than HK in cancer cells. Thus, GLUT seems a more adequate therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681047     DOI: 10.1002/jcp.21885

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  25 in total

1.  N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4.

Authors:  Yoshimi Haga; Kumiko Ishii; Tadashi Suzuki
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

2.  In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Authors:  Rama K Mishra; Changyong Wei; Richard C Hresko; Richa Bajpai; Monique Heitmeier; Shannon M Matulis; Ajay K Nooka; Steven T Rosen; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

3.  Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers.

Authors:  Anna-Maria Rolle; Peter T Soboslay; Gerald Reischl; Wolfgang H Hoffmann; Bernd J Pichler; Stefan Wiehr
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

4.  18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Misu Lee; Jeong Yong Jeon; Micheal L Neugent; Jung-Whan Kim; Mijin Yun
Journal:  Clin Exp Metastasis       Date:  2017-04-20       Impact factor: 5.150

5.  Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI.

Authors:  Joshua M Goldenberg; Mark D Pagel; Julio Cárdenas-Rodríguez
Journal:  Magn Reson Med       Date:  2018-01-25       Impact factor: 4.668

6.  A unifying modelling formalism for the integration of stoichiometric and kinetic models.

Authors:  Jorge Júlvez; Stephen G Oliver
Journal:  J R Soc Interface       Date:  2020-08-05       Impact factor: 4.118

7.  [6]-Gingerol inhibits de novo fatty acid synthesis and carnitine palmitoyltransferase-1 activity which triggers apoptosis in HepG2.

Authors:  Hathaichanok Impheng; Lysiane Richert; Dumrongsak Pekthong; C Norman Scholfield; Sutatip Pongcharoen; Ittipon Pungpetchara; Piyarat Srisawang
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

8.  Development of GLUT4-selective antagonists for multiple myeloma therapy.

Authors:  Changyong Wei; Richa Bajpai; Horrick Sharma; Monique Heitmeier; Atul D Jain; Shannon M Matulis; Ajay K Nooka; Rama K Mishra; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  Eur J Med Chem       Date:  2017-08-14       Impact factor: 6.514

Review 9.  The Warburg effect revisited--lesson from the Sertoli cell.

Authors:  Pedro F Oliveira; Ana D Martins; Ana C Moreira; C Yan Cheng; Marco G Alves
Journal:  Med Res Rev       Date:  2014-07-12       Impact factor: 12.944

Review 10.  Glucose transporters in cancer metabolism.

Authors:  Kehinde Adekola; Steven T Rosen; Mala Shanmugam
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.